Document:

EX-10.12

 Exhibit 10.12 

EMPLOYMENT AGREEMENT 

This Employment Agreement (the “Agreement”) dated as of July
_, 2018 is effective as of the Commencement Date (defined below) between Cano Health, LLC (d/b/a Cano Health), a Delaware limited liability corporation (together with its subsidiaries, the “Company”), and David Armstrong (the
“Executive”).  
 l. Employment. 

(a) Term. The Company hereby employs the Executive, and the Executive hereby accepts such employment, on the terms set forth herein
commencing on the Commencement Date (defined below) and continuing until terminated in accordance with the provisions of Section 3 hereof (the ‘‘Term”). The “Commencement
Date” shall be the earlier of September 4, 2018 or such date as mutually agreed by the parties. The Company’s agreement to employ the Executive is contingent on Company’s completing a background check of the
Executive, to the satisfaction of the Company, prior to the Commencement Date. 
 (b) Position and Duties. During the Term, the
Executive shall serve as Senior Vice President. General Counsel and Chief Compliance Officer of the Company, and shall have supervision and primary responsibility over the legal and compliance related affairs of the Company, including the
maintenance of the Company’s compliance plan and such other powers and duties as may from time to time be prescribed by the Chairman of the Board of Managers of the Company’s parent, Primary Care (ITC) Holdings LLC (the
“Board”), the Chief Executive Officer of the Company (the “CEO”) or other authorized executive, provided that such duties are consistent with the
Executive’s position or other positions that he may hold from time to time. The Executive shall report directly to the CEO. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding
the foregoing, the Executive may engage in such activities as are approved in writing by the CEO or the Board and to engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and
do not materially interfere with the Executive’s performance of his duties to the Company as provided in this Agreement. The Executive shall work primarily from the Company’s offices which will be located in Dade County, Florida;
provided that the Executive will be required from time-to-time to travel to the Company’s offices in other locations, and otherwise to fulfill the duties of
his position. 
 2. Compensation and Related Matters. 

(a) Base Salary. During the Term, the Executive’s initial base salary shall be $232,500.00 (two hundred thirty-two thousand five hundred dollars) annually, subject to discretionary increases as a result of annual reviews by the Board (the “Base
Salary”). Base Salary will be increased to not less than $235,000.00 in conjunction with Executive’s annual review which the Company agrees to complete in January 2019. The Base Salary shall be payable
in a manner that is consistent with the Company’s usual payroll practices for senior executives. 
 (b) Annual Bonus. The
Executive shall be eligible to receive an annual performance bonus for 2018 and each calendar year during the Term thereafter based upon the Company’s achievement of EBITDA targets and the Executive’s achievement of metrics relevant

  

					
		  		  	

 
to Executive’s position to be established jointly between Company and Executive, and achievement approved by the Board in its sole and reasonable discretion (the “Annual
Bonus”). For 2018, the Annual bonus will be prorated and measured from the Commencement Date through December 31, 2018. The Executive’s target bonus for 2018 and each year of the Term thereafter shall be 30% of his Base
Salary. To earn any such annual bonus, the Executive must be employed by the Company on the date such bonus is paid (and not having provided the Company with notice prior to the payment date of Executive’s intent to terminate his employment),
which shall be within thirty (30) of the completion of the Company’s financial audit for the calendar year to which the Annual Bonus pertains. 

(c) Purchased Equity; Incentive Equity Grant. Within ninety (90) days of the Commencement Date, the Executive may exercise an
option to purchase and purchase up to $100,000 worth of Class A-4 Units of Primary Care (ITC) Holdings, LLC (the “Parent”) at the then current fair market value price
per Class A-4 Unit as determined by the Board in its sole and reasonable discretion (the “Executive Purchased Equity”) and in accordance with the terms
of a subscription agreement in form and substance satisfactory to the Company. On the date Executive purchases the Executive Purchased Equity (assuming Executive exercises the right to purchase described above), the Parent will provide Executive
with a loan of up to 50% of the purchase price for the purchase of the Executive Purchased Equity (the “Loan”), and in consideration therefor, Executive hereby agrees to deliver to the Parent a promissory note
and pledge agreement in form and substance satisfactory to Parent (the “Loan Documents”). Notwithstanding the Loan, all Executive Purchased Equity shall be fully vested on the date the purchase is completed, but
subject to any repurchase or other rights of the Parent set forth in the Equity Documents (as defined herein). Further, on the Commencement Date, at no cost to Executive the Parent shall issue Executive 15,000 Class B Units (profits interest
units) of the Parent (the “Executive Incentive Equity” and, together with the Executive Purchased Equity, they shall be referred to collectively as the “Executive Equity”).
The Executive Equity will be subject to the terms and conditions of the Parent’s limited liability company agreement and the Executive Incentive Equity will be subject to the terms and conditions of the equity grant agreement (the
“Equity Documents”) and will be contingent upon the approval of the Board of Managers of the Parent. The issuance of the Executive Equity will be contingent upon the Executive agreeing to be bound by the
applicable Equity Documents. which shall include, without limitation, the right of the Parent to repurchase the Executive Equity as set forth therein. 

(d) Business Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him
during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executives. Notwithstanding the foregoing, during the Term, the Company shall reimburse
Executive for not less than the following business expenses: professional license renewal fees; continuing education; and professional memberships .. 

(e) Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s
employee benefit plans that are offered to other senior executives of the company and that are in effect from time to time, subject to the terms of such plans. Notwithstanding the foregoing, during the Term the Company shall provide Executive not
less than the following benefits, family health, dental and vision insurance to include Executive, spouse and dependents; and, life and short and long term disability insurance covering Executive. 

  

					
		  	2	  	

 (f) Paid Time Off; Holidays. During the Term, the Executive shall be entitled to
accrue up to twenty (20) days of paid time off (“PTO”) in each calendar year which shall be accrued ratably per pay period. Unused PTO cannot be carried over to the next calendar year and all
unused PTO remaining at the end of a calendar year will be forfeited. The Executive shall also be entitled to all paid holidays given by the Company to its executives. 

(g) Indemnification. The Executive shall be entitled to receive coverage under the Company’s applicable insurance policies and
shall also be entitled to customary officers’ and directors’ indemnification coverage (including for the costs of any litigation incurred in the Executive’s capacity as a director or officer of the Company or of the Parent) under the
Company’s and the Parent’s respective limited liability company agreements. 
 (h) LLC Personal Tax Liabilities. The
Parent’s limited liability company agreement shall provide for tax distributions to the Executive in order for the Executive to be able to pay any tax liabilities that result from any allocations or distributions made to the Executive under the
Parent’s limited liability company agreement. 
 3. Termination. During the Term, the Executive’s employment hereunder may be
terminated effective on the Date of Termination (defined below) without any breach of this Agreement under the following circumstances: 

(a) Death. The Executive’s employment hereunder shall terminate upon his death. 

(b) Disability. The Company may terminate the Executive’s employment if he is disabled and unable to perform the essential
functions of the Executive’s then existing position or positions under this Agreement with reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any
question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with reasonable accommodation, the Executive may, and at
the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so
disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with
such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to
waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 

 (c) Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause (defined
below). 
 (d) Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without
Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) shall be deemed a termination without Cause. 

  

					
		  	3	  	

 (e) Termination by the Executive. The Executive may terminate his employment
hereunder at any time for any reason, including but not limited to Good Reason (defined below). 
 (f) Notice of Termination. Except
for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination (defined below) to the other party
hereto. 
 (g) Definitions. 

(i) “Cause” shall mean any one or more of the following as determined by a vote of the majority of the
Board: (A) conduct by the Executive constituting a material act of misconduct in connection with the performance of his duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or
affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (B) the commission by the Executive of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or any
conduct by the Executive that in Company’s reasonable discretion would be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates if he were retained in his position;
(C) continued non-performance by the Executive of his duties hereunder (other than by reason of the Executive’s physical or mental illness, incapacity or disability) which has continued for more than
fifteen (15) days following written notice of such non-performance from the Board or the CEO; (D) a breach by the Executive of any of the provisions contained in Section 6 of this Agreement;
(E) a material violation by the Executive of the Company’s written employment policies ; (F) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being
instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other
materials in connection with such investigation; (G) inability of the Executive to perform their duties due to the abuse of alcohol, illegal drugs, or illegal controlled substances; or (H) any action by the Executive not taken in good
faith, or the Executives willful misconduct or gross negligence of the Executive’s duties, in any case, that in the Company’s reasonable discretion would be expected to materially injure the business, financial condition, or operations of
the Company. 
 (ii) “Date of Termination” shall mean: (A) if the Executive’s employment
is terminated by his death, the date of his death; (B) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of
Termination is given; (C) if the Executive’s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given, and (D) if the Executive’s employment is terminated
by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given and (E) if the Executive’s employment is terminated by the Executive under section 3(e) with Good Reason, the
date on which a notice of termination is given after the end of the Cure Period (defined below). Notwithstanding the foregoing, in the event that the Executive gives a Notice of 

  

					
		  	4	  	

 Termination to the Company, the Company may unilaterally accelerate the Date of Termination
and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 
 (iii)
“Good Reason” shall mean that the Executive has complied with the Good Reason Process (defined below) following the occurrence of any of the following events: (A) a
diminution in the Executive’s duties, responsibilities or authority as Senior Vice President and General Counsel; (B) a diminution in the Executive’s Base Salary; (C) a permanent relocation of the Company’s offices to which
the Executive must principally report to a geographic location that is outside of Dade County, Broward County or Palm Beach County, Florida; or (D) the material breach of this Agreement by the Company. 

(iv) “Good Reason Process” shall mean that (A) the
Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (B) the Executive notifies the Company in writing of the occurrence of the Good Reason condition within thirty (30) days of the occurrence
of such condition; (C) the Executive cooperates in good faith with the Company’s efforts, for a period not less than thirty (30) days following such notice (the “Cure
Period”), to remedy the condition if such condition is capable of being remedied; (D) notwithstanding such efforts, the Good Reason condition continues to exist; and (E) the Executive
terminates his employment within thirty (30) days after the end of the Cure Period. If the Company cures the Good Reason condition to the mutual and reasonable satisfaction of the parties during the Cure Period, Good Reason shall be deemed not
to have occurred. 
 (v) “Notice of Termination” shall mean
a notice which shall indicate the specific termination provision in this Agreement relied upon. 
 4. Compensation Upon Termination. 

(a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or
provide to the Executive (or to his authorized representative or estate) (i) any Base Salary and Bonus earned through the Date of Termination, unused PTO that has accrued as of the Date of Termination and any unpaid expense reimbursements
(subject to, and in accordance with, Section 2(c) of this Agreement) on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may
have under any employee benefit plan of the Company through the Date of Termination which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the
“Accrued Benefit”).  
 (b) Termination by the Company Without Cause or
by the Executive with Good Reason. If the Executive’s employment is terminated by the Company without Cause under Section 3(d), or the Executive terminates his employment for Good Reason under Section 3(e), then the Company shall
pay the Executive as provided in Section 4(a)(i) and (ii) and, in addition, subject to the Executive signing a general release of claims in favor of the Company and related persons and entities and
non-disparagement, in the form attached hereto as Exhibit A (the “Release”) and the Release becoming irrevocable, all within 60 days
after the Date of Termination, 

  

					
		  	5	  	

 the Company shall continue paying the Executive his final Base Salary as effective on the Date of
Termination for twelve (12) months and pay for continuation of the Section 2(e) Other Benefits including COBRA continuation for health benefits for such twelve (12) month period (“Salary
Continuation”). The twelve (12) month period (“Salary Continuation Period”) shall commence on the Company’s first regular payroll date following
the effective date of the Release. Tax-related deductions and withholdings will apply to Salary Continuation. Salary Continuation is subject to Executive making commercially reasonable efforts to seek
employment during the Salary Continuation Period and if Executive commences employment with another employer during the Salary Continuation Period, then Executive shall provide notice of such new employment arrangement to Company and Company shall
thereafter be released from making any further Salary Continuation payments to Executive. In addition, within fifteen (15) days from the Date of Termination under Sections 3(d) or (3)(e), with the exception of Termination due to Death or
Disability, Company shall notify Executive in writing of its decision to reduce the Salary Continuation Period to a period between six (6) months and twelve (12) months, provided in which case the Noncompete Period (as defined herein) shall
likewise be reduced by a corresponding duration, so that the Salary Continuation Period and the Noncompete Period run concurrently. For the avoidance of doubt, the parties agree that in no event shall the Salary Continuation Period be less than six
(6) months. 
 5. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Internal Revenue Code (the “Code”), the Company determines that the Executive is a “specified employee” within the meaning of
Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation
otherwise subject to the twenty (20) percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit
shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an
installment basis, the first payment shall include a catchup payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance
of the installments shall be payable in accordance with their original schedule. 
 (b) All in-kind
benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid during the time
periods as set forth in this Agreement, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of
in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for
reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or
exchange for another benefit. 

  

					
		  	6	  	

 (c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments
or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury
Regulation Section 1.409A-1 (h). 
 (d) The parties intend that this Agreement will be
administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The
parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and
benefits provided hereunder without additional cost to either party. 
 (c) The Company makes no representation or warranty and shall have
no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such
Section. 
 6. Restrictive Covenants. 

(a) Confidential Information. As used in this Agreement, “Confidential Information” means information belonging
to the Company which is of value to the Company in the course of conducting its business and the disclosure of which could result in a competitive or other disadvantage to the Company. Confidential Information includes, without limitation, financial
information, reports, and forecasts; inventions, improvements and other intellectual property; trade secrets; know-how; designs, processes or formulae; software; market or sales information or plans; customer
lists; and business plans, prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) which have been discussed or considered by the management of the Company. Confidential Information includes
information developed by the Executive in the course of the Executive’s employment by the Company, as well as other information to which the Executive may have access in connection with the Executive’s employment. Confidential Information
also includes the confidential information of others with which the Company has a business relationship. Notwithstanding the foregoing, Confidential Information does not include information in the public domain, unless due to breach of the
Executive’s duties under Section 6(b). 
 (b) Confidentiality. The Executive understands and agrees that the
Executive’s employment creates a relationship of confidence and trust between the Executive and the Company with respect to all Confidential Information. At all times, both during the Executive’s employment with the Company and after its
termination, the Executive will keep in confidence and trust all such Confidential Information, and will not use or disclose any such Confidential Information without the written consent of the Company, except as may be necessary in the ordinary
course of performing the Executive’s duties to the Company. For avoidance of doubt, nothing in this 

  

					
		  	7	  	

 Agreement shall be interpreted or applied to prohibit the Executive from making any good faith report to any
governmental agency or other governmental entity concerning any act or omission that the Executive reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation
or whistleblower provisions of applicable federal or state law or regulation. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any
federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney and (B) solely for the
purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

(c) Documents, Records, etc. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining
to Confidential Information, which are furnished to the Executive by the Company or arc produced by the Executive in connection with the Executive’s employment will be and remain the sole property of the Company. The Executive will return to
the Company all such materials and property as and when requested by the Company. In any event, the Executive will return all such materials and property immediately upon termination of the Executive’s employment for any reason. The Executive
will not retain with the Executive any such material or property or any copies thereof after such termination. 
 (d) Noncompctition;
Nonsolicitation. 
 (i) During the Term and for twelve (12) months thereafter (the “Noncompete
Period”), regardless of the reason for the termination of the Executive’s employment, with the exception of Death or Disability, the Executive will not, without the express written approval of the CEO or the Board, directly or
indirectly, whether as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise, engage, participate, assist or invest in any Competing Business (as hereinafter defined).
“Competing Business” shall mean a business conducted in any Restricted Territory that is engaged primarily in the ownership and operation of a primary care medical practice and is licensed to provide and does
actively provide professional medical services, diagnostic, therapeutic and ancillary services, nursing and other clinical services, outpatient healthcare services, pharmacy services and all other services pertaining to the operation of a primary
care medical practice and that competes with Company within a Restricted Territory. “Restricted Territory” shall mean Miami-Dade, Broward, and Hillsborough counties and other Medicare Advantage service areas in
the State of Florida and any other state in which the Company has clinical operations as of the Date of Termination. Notwithstanding the foregoing, the Executive may passively invest in the outstanding stock of a publicly held corporation which
constitutes or is affiliated with a Competing Business. The running of the Noncompete Period shall be extended by the time during which the Executive engages in a violation of this section. 

(ii) During the Term and for twenty-four (24) months thereafter (the
“Non-solicit Period”), regardless of the reason for the termination of the Executive’s employment, the Executive will refrain from (A) directly or indirectly
employing, attempting to employ, recruiting or otherwise soliciting, inducing or influencing any person 

  

					
		  	8	  	

 to leave employment with the Company (other than terminations of employment of subordinate
employees undertaken in the course of the Executive’s employment with the Company); and (B) soliciting or encouraging any customer, supplier or payer to terminate or otherwise modify adversely its business relationship with the Company or
any company included as of the Date of Termination in the Company’s then-current acquisition pipeline. The running of the Non-solicit Period shall be extended by the time during which the Executive
engages in a violation of this section. 
 (iii) The Executive understands that the restrictions set forth in this
Section 6(d) are intended to protect the Company’s interest in its Confidential Information and established employee, customer and supplier relationships and goodwill, and agrees that such restrictions are reasonable and appropriate for
this purpose. 
 (e) Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is not bound by the terms of
any agreement with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information or the Executive’s engagement in the Company’s business. The Executive represents to the Company that
the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such
previous employer or other party. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the
Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party. 

(f) Litigation and Regulatory Cooperation. During and after the Term, the Executive shall cooperate fully with the Company in the
defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company. The
Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to , being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually
convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such
investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable
out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 6(f). The Company shall agree with
Executive on reasonable compensation for any such engagement lasting more than 24 hours. 
 (g) Injunction. The Executive agrees that
it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the promises set forth in this Section 6, and that in any event money damages would be an inadequate remedy for any such
breach. Accordingly, if the Executive breaches, or proposes to breach, any portion of this Section 6, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to
restrain any such breach without showing or proving any actual damage to the Company. 

  

					
		  	9	  	

 7. Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the state and
federal courts of Florida. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether
imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. 
 8. Integration. This
Agreement, together with the Equity Documents, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter. 

9. Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be
withheld by the Company under applicable law. 
 10. Successor to the Executive. This Agreement shall inure to the benefit of and be
enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the
Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such
designation). 
 11. Enforceability; Effectiveness. If any portion or provision of this Agreement (including, without limitation, any portion
or provision of any section of this Agreement) shall to any ex tent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances
other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. If the Executive fails to
complete a background check to the satisfaction of the Company, this Agreement shall automatically become null and void and of no further force and effect. 

12. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s
employment to the extent necessary to effectuate the terms contained herein. 
 13. Waiver. No waiver of any provision hereof shall be
effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any
subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach . 
 14. Notices. Any notices, requests,
demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return
receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the CEO or the Board. 

  

					
		  	10	  	

 15. Amendment. This Agreement may be amended or modified only by a written instrument signed
by the Executive and by a duly authorized representative of the Company. 
 16. Governing Law. This is a Florida contract and shall be
construed under and be governed in all respects by the laws of the State of Florida, without giving effect to the conflict of laws principles of such State. With respect to any disputes concerning federal law, such disputes shall be determined in
accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the Eleventh Circuit. 
 17.
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. Faxed,
scanned, emailed, pdf’s and copies shall be binding as originals. 
 18. Successor to Company. The Company shall require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be
required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement. 

[signature page follows] 

  

					
		  	11	  	

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year
first above written. 
  

			
	 CANO HEALTH, LLC

		
	 By:
	 	 /s/ Marlow Hernandez

	 Its:
	 	 Chief Executive Officer

	
	 EXECUTIVE

	
	 /s/ David Armstrong

	 David Armstrong

 [SIGNATURE PAGE TO EMPLOYMENT AGREEMENT] 

  
 12 

 Exhibit A 

RELEASE 
 I enter into
this Separation Agreement (the “Release”) pursuant to Section 4 of the Employment Agreement between Cano Health LLC (the “Employer”) and me dated [DATE], 2018 (the “Employment Agreement”). I
acknowledge that my timely execution and return [and my non-revocation] of this Release are conditions to the payment of the “Salary Continuation” and other post-employment benefits described
in Section 4 of the Employment Agreement. I therefore agree to the following terms: 
 1. Release of Claims. I voluntarily
release and forever discharge the Employer, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former
officers, directors, shareholders, members, employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively referred to as the ‘‘Releasees”) generally from all
claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when I sign this Release, I have, ever had, now claim to have or ever claimed to have had against any or all
of the Releasees. This release includes, without limitation, all Claims: 
  

	•	 	 relating to my employment by the Employer and/or any affiliate of the Employer and the termination of my
employment; 

  

	•	 	 of wrongful discharge; 

 

	•	 	 of breach of contract; 

 

	•	 	 of retaliation or discrimination under federal , state or local law (including, without limitation, Claims of age
discrimination or retaliation under the [Age Discrimination in Employment Act,] Claims of disability discrimination or retaliation under the Americans with Disabilities Act, Claims of discrimination or retaliation under Title VII of the Civil Rights
Act of 1964, Claims of any form of discrimination or retaliation that is prohibited by the Florida Civil Rights Act, Florida Whistleblower Protection Act, Florida Workers’ Compensation Retaliation Provision, Article X, Section 24 of the
Florida Constitution, and the Florida Fair Housing Act); 

  

	•	 	 under any other federal or state statute; 

 

	•	 	 of defamation or other torts; 

 

	•	 	 of violation of public policy; 

 

	•	 	 for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other compensation or
benefits, including under the Florida Minimum Wage Act (except for such wages, bonuses, incentive compensation, stock, stock options, vacation pay or other compensation or benefits otherwise due to me under the Employment Agreement); and

  

	•	 	 for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages,
injunctive relief and attorney’s fees ; 

 provided, however, that this release shall not affect my rights under the
Employment Agreement, nor shall it affect any Claim that by express terms of law may not be waived. 

  

					
		  	13	  	

 I agree that I shall not seek or accept damages of any nature, other equitable or legal remedies for my own
benefit, attorney’s fees, or costs from any of the Releasees with respect to any Claim released by this Agreement. 
 2. Protected
Disclosures. Nothing contained in this Agreement limits my ability to file a charge or complaint with any federal, state or local governmental agency or commission (a “Government Agency”). In addition, nothing contained in this
Agreement limits my ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including my ability to provide documents or other information, without
notice to the Company, nor does anything contained in this Agreement apply to truthful testimony in litigation. lf I file any charge or complaint with any Government Agency and if the Government Agency pursues any claim on my behalf, or if any other
third party pursues any claim on my behalf, I waive any right to monetary or other individualized relief (either individually, or as part of any collective or class action). Further, for the avoidance of doubt pursuant to the federal Defend Trade
Secrets Act of 2016, I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official,
either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such
filing is made under seal. 
 3. Ongoing Obligations. I reaffirm my ongoing obligations to the Company and the Parent (as defined in
the Employment Agreement), including under the Employment Agreement and any Equity Documents (as defined in the Employment Agreement). 
 1.
No Assignment. I represent that I have not assigned to any other person or entity any Claims against any Releasee. 
 2. Right to
Consider and Revoke Release. I acknowledge that I have been given the opportunity to consider this Release for a period of 21 days from the date when it is tendered to me. In the event that I executed this Release within less than 21 days, I
acknowledge that such decision was entirely voluntary and that I had the opportunity to consider this Release until the end of the 21-day period. To accept this Release, I shall deliver a signed Release to the
Employer’s Chief Executive Officer within such 21-day period; provided that I acknowledge that the Employer may change the designated recipient by notice. For a period of seven days from the date
when I execute this Release (the “Revocation Period”), I shall retain the right to revoke this Release by written notice that is received by the Employer’s Chief Executive Officer on or before the last day of the Revocation
Period. This Release shall take effect only if it is executed within the 21-day period as set forth above and if it is not revoked pursuant to the preceding sentence. If those conditions are satisfied, this
Release shall become effective and enforceable on the date immediately following the last day of the Revocation Period. 
 3. Other Terms.

 (a) Legal Representation; Review of Release. I acknowledge that I have been advised to discuss all aspects of this Release with my
attorney, that I have carefully read and fully understand all of the provisions of this Release and that I am voluntarily entering into this Release. 

  

					
		  	14	  	

 (b) Binding Nature of Release. This Release shall be binding upon me and upon my
heirs, administrators, representatives and executors. 
 (c) Amendment. This Release may be amended only upon a written agreement
executed by the Employer and me. 
 (d) Severability. In the event that at any future time it is determined by an arbitrator or court
of competent jurisdiction that any covenant, clause, provision or term of this Release is illegal, invalid or unenforceable, the remaining provisions and terms of this Release shall not be affected thereby and the illegal, invalid or unenforceable
term or provision shall be severed from the remainder of this Release. In the event of such severance, the remaining covenants shall be binding and enforceable. 

(e) Governing Law and Interpretation. This Release shall be deemed to be made and entered into in the State of Florida, and shall in
all respects be interpreted, enforced and governed under the laws of the State of Florida, without giving effect to the conflict of laws principles of such state. The language of all parts of this Release shall in all cases be construed as a whole,
according to its fair meaning, and not strictly for or against either the Employer or me. 
 (f) Absence of Reliance. I acknowledge
that I am not relying on any promises or representations by the Employer or any of its agents. representatives or attorneys regarding any subject matter addressed in this Release. 

So agreed. 
  

							
	David Armstrong	 		  	            Date	  	

  

					
		  	15EX-10.13

 Exhibit 10.13 

AMENDED AND RESTATED 

RIGHT OF FIRST REFUSAL AGREEMENT 

This AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AGREEMENT (this “Agreement”) is made as
of                , 2021 (the “Effective Date”), by and among (i) Humana Inc., Humana Medical Plan, Inc., Humana Health Insurance Company of
Florida, Inc., and Humana Insurance Company and their Affiliates who underwrite and/or administer health plans (collectively, “Humana”), (ii) Primary Care (ITC) Holdings, LLC (“Cano”), (iii) Primary Care (ITC)
Intermediate Holdings, LLC (“Cano Intermediate”), and (iv) Cano Health, Inc., formerly known as Jaws Acquisition Corp. (“Pubco”). 

WHEREAS, Humana and HP MSO, LLC (“Healthy Partners”) are party to that certain Physician Practice Management
Participation Agreement, effective as of June 1, 2003, as amended by that certain Addendum, effective as of January 1, 2018 (as amended, the “Participation Agreement”), pursuant to which Humana has the right of first
refusal to purchase Healthy Partners, on the terms and conditions described in the Participation Agreement (the “HP ROFR”); 

WHEREAS, on July 1, 2019, Humana received a written notice from Healthy Partners (the “HP Offer Notice”), which
written notice stated that (i) an affiliate of Cano had delivered a letter of indication (the “HP LOI”) to acquire Healthy Partners (the “HP Acquisition”) on the terms and conditions set forth in the HP LOI,
and (ii) the HP LOI had triggered the HP ROFR and a thirty (30) day review period (following Humana’s receipt of the HP Offer Notice) for Humana to elect to exercise the HP ROFR triggered by the HP LOI (the “HP Review
Period”); 
 WHEREAS, Humana and Healthy Partners agreed to extend the HP Review Period triggered by the HP Offer Notice
until 11:59 p.m. Louisville, Kentucky time on September 22, 2019 (the “HP Extended Review Period”); provided that each of Humana and Healthy Partners had the option to terminate the HP Extended Review Period early
by giving written notice to the other party of its intention to do so not later than 5:00 p.m. Louisville, Kentucky time on August 9, 2019 (the “Extended Review Termination Deadline”), in which case the HP Extended Review
Period shall have been deemed to expire at 12:00 p.m. (noon) Louisville, Kentucky time on August 12, 2019 (the “Early Termination Time”); 

WHEREAS, Healthy Partners terminated the HP Extended Review Period by giving written notice to Humana of its intention to do so prior
to the Extended Review Termination Deadline, and therefore the HP Extended Review Period is deemed to have expired at the Early Termination Time; 

WHEREAS, Humana and Cano entered into that certain Right of First Refusal Agreement, dated as of August 16, 2019, as amended by
that certain Amendment No. 1 to the Right of First Refusal Agreement, dated as of March 17, 2020, by and between Cano and Humana (collectively, the “Prior ROFR Agreement”); 

WHEREAS, each of Cano, Cano Intermediate, Pubco and Humana Inc. entered into that certain letter agreement, dated as of
November 11, 2020, pursuant to which, among other things, Cano, Cano Intermediate, Pubco and Humana agreed to amend and restate the Prior ROFR Agreement in accordance with the terms set forth therein; 

  
 1 

 WHEREAS, Section 6.5 of the Prior ROFR Agreement provides that the Prior ROFR
Agreement may be amended by an instrument in writing executed by Humana and Cano; and 
 WHEREAS, Humana and Cano desire to amend and
restate the Prior ROFR Agreement, and each of Cano Intermediate and Pubco desire to enter into this Agreement, in each case, on the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the premises and mutual promises and agreements hereinafter set forth, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree, and each of Cano and Humana agree that that Prior ROFR Agreement is hereby amended and restated, in each case, as follows: 

1. DEFINITIONS. The following terms, when used herein, have the meanings set forth below. 

“Affiliate” means any company, individual, corporation, partnership, association, or business that now or hereafter directly,
or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with another person; and the term “control,” including the terms “controlling,” “controlled by,” and
“under common control with,” means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting shares, by contract or otherwise. 

“Definitive Agreement” means a legally binding definitive agreement with respect to a Sale Transaction and, for the avoidance
of doubt, does not include any non-binding term sheet reflecting the terms and conditions of the proposed Sale Transaction and/or a customary confidentiality agreement with any potential acquirer;
provided that such term sheet or similar document does not include binding exclusivity provisions that would preclude Cano, Cano Intermediate, Pubco or any of their Members or its or their respective Affiliates (including Healthy Partners
following any HP Acquisition) from complying with the terms of this Agreement. 
 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 “Members” means, with respect to
a Person, the direct and indirect “beneficial owners” (as such term is defined in Rule 13d-3 and Rule 13d-5 promulgated under the Securities Exchange Act) of
equity securities of such Person. 
 “Person” means an individual, corporation, partnership, limited partnership, limited
liability company, syndicate, person (including, without limitation, a “person” as defined in Section 13(d)(3) of the Exchange Act), trust, association or entity or government, political subdivision, agency or instrumentality of a
government. 
 “Sale Process” means a process initiated by a Selling Party for the bona fide purpose of seeking one or more
offers or proposals relating to any Sale Transaction, whether solicited directly or through an investment bank engaged to act on behalf of such Selling Party. 
  

  
 2 

 “Sale Transaction” means any of (i) the sale, lease, license,
transfer, conveyance or other disposition, directly or indirectly, in one transaction or a series of related transactions, of assets, businesses, divisions or subsidiaries that constitute 20% or more of the net revenues, net income or assets of
(x) Cano, Cano Intermediate or Pubco (in each case, including its respective subsidiaries and controlled Affiliates, taken as a whole), or (y) to the extent that any such transaction occurs following the consummation of any HP Acquisition,
Healthy Partners and its subsidiaries and controlled Affiliates, taken as a whole, (ii) a transaction or a series of related transactions (including by way of merger, consolidation, recapitalization, exchange offer, spin-off, split-off, reorganization or sale of securities) the result of which is that (x) the Members of Cano, Cano Intermediate or Pubco or, in each case, their
respective Affiliates immediately prior to such transaction or series of related transactions are (after giving effect to such transaction or series of related transactions) no longer, in the aggregate, the “beneficial owners” (as such
term is defined in Rule 13d-3 and Rule 13d-5 promulgated under the Securities Exchange Act), directly or indirectly through one or more intermediaries, of more than 50%
of the voting power of the outstanding equity securities of Cano, Cano Intermediate or Pubco, respectively or (y) to the extent that any such transaction occurs following the consummation of any HP Acquisition, the holders of Healthy
Partner’s outstanding equity securities or their Affiliates immediately prior to such transaction or series of related transactions are (after giving effect to such transaction or series of related transactions) no longer, in the aggregate, the
“beneficial owners” (as such term is defined in Rule 13d-3 and Rule 13d-5 promulgated under the Securities Exchange Act), directly or indirectly through one or
more intermediaries, of more than 50% of the voting power of the outstanding equity securities of Healthy Partners or (iii) any other transaction having a similar effect to those described in the foregoing clauses (i) and (ii). 

2. WAIVER OF HP ROFR. 
 Humana hereby (x) waives the
HP ROFR and (y) consents to the assignment of any contract or agreement that it maintains with Healthy Partners or any of its Affiliates, including, without limitation, the Participation Agreement, to Cano or any of its controlled Affiliates
upon consummation of transactions contemplated by the HP Acquisition, in each case solely with respect to an HP Acquisition that is consummated on the terms and conditions for such HP Acquisition that are set forth in the HP LOI; provided,
that the foregoing waiver does not constitute any waiver of rights that Humana and its Affiliates may have with respect to (x) any HP Acquisition that is consummated on terms and conditions for such HP Acquisition that are different in any
material respect from those set forth in the HP LOI or (y) any other or subsequent Sale Transaction. 
 3. RIGHT OF FIRST REFUSAL. 

3.1 From and after the Effective Date, if at any time Cano, Pubco, Cano Intermediate, or any of their respective Affiliates or controlling
Members (each, as applicable, a “Selling Party” and collectively the “Selling Parties”) enters into a Definitive Agreement for a proposed Sale Transaction, then the Selling Parties hereby grant to Humana (or its
designated Affiliate) a right of first refusal with respect to such proposed Sale Transaction (the “Option”) in accordance with the following provisions: 

(a) The applicable Selling Parties shall, contemporaneously with entering into such Definitive Agreement, provide to Humana a written notice
(an “Acquisition Notice”) stating (i) their intention to consummate the Sale Transaction on the terms and conditions contemplated by such Definitive Agreement, (ii) the identity of the prospective acquiror in the proposed
Sale Transaction (the “Proposed Acquiror”), (iii) the bona fide purchase price proposed to be paid by the Proposed Acquiror in the proposed Sale Transaction (the “Offered Price”) and (iv) the other
material terms and conditions, including those set forth in such Definitive Agreement, upon which the proposed Sale Transaction is proposed to be made (the “Offered Terms”). The Acquisition Notice shall also include a copy of the
applicable Definitive Agreement and any related documents. 
  

  
 3 

 (b) Humana (or its designated Affiliate) may elect, by providing written notice to the
applicable Selling Parties (an “Election Notice”) at any time within the longer of (w) in the event that the Selling Parties enter into a Definitive Agreement for a proposed Sale Transaction with a Proposed Acquiror, ninety
(90) calendar days following Humana’s receipt of all material non-public diligence information provided by, or on behalf of, the Selling Parties to such Proposed Acquiror in connection with the
proposed Sale Transaction, (x) ninety (90) calendar days after the Sale Process Initiation Date, (y) solely in the event that the Selling Parties enter into a Definitive Agreement for a proposed Sale Transaction with a Proposed Acquiror in
connection with a Sale Process, thirty (30) calendar days after the date that the Selling Parties provide an Acquisition Notice to Humana pursuant to Section 3.1(a) and (z) solely in the event that the Selling
Parties enter into a Definitive Agreement for a proposed Sale Transaction with a Proposed Acquiror outside of a Sale Process, ninety (90) calendar days after the date that the Selling Parties provide an Acquisition Notice to Humana pursuant to
Section 3.1(a) (the “Election Period”), to engage in the Sale Transaction contemplated by the Definitive Agreement with the applicable Selling Parties in lieu of the Proposed Acquiror at the Offered Price
and on the Offered Terms, the intention of the foregoing being that Humana shall have ninety (90) calendar days to take such actions as are reasonably necessary in order for it to determine whether or not to provide an Election Notice to the
applicable Selling Parties; provided that in the event an Option Lapse occurs in connection with a Sale Process, if Humana subsequently obtains another Option as contemplated by the proviso to Section 3.1(c) and
Section 3.1(d), and thereafter receives an Acquisition Notice pursuant to Section 3.1(a) that arises from the same Sale Process, then the Election Period with respect to such Option shall be
the later of (x) thirty (30) calendar days after the date that the Selling Parties provide such Acquisition Notice and (y) thirty (30) calendar days after Humana’s receipt of all material
non-public diligence information provided by, or on behalf of, the applicable Selling Parties to such Proposed Acquiror in connection with the proposed Sale Transaction. Notwithstanding anything herein to the
contrary, if the Offered Price specified in the Acquisition Notice is payable in a form of consideration other than cash, Humana (or its designated Affiliate) shall have the right to pay such Offered Price in an amount of cash equal to the fair
market value of such consideration, as mutually determined in good faith by the applicable Selling Parties and Humana during the Election Period; provided that if Humana and the applicable Selling Parties are unable to agree on the fair
market value of such consideration during the Election Period, then Humana and the applicable Selling Parties shall appoint an independent appraiser to determine the fair market value of such consideration (which must be an amount between or equal
to the amounts proposed by the applicable Selling Parties and Humana), which determination shall be deemed to be final, binding and unreviewable for all purposes under this Agreement, including for purposes of this
Section 3.1(b); provided, further, that if such independent appraiser’s determination does not exceed the fair market value proposed by Humana to the independent appraiser by at least ten percent (10%),
the applicable Selling Parties will reimburse Humana for all costs of the appraisal; otherwise, the applicable Selling Parties and Humana will each bear 50% of the costs of the appraisal. 

 

  
 4 

 (c) If Humana does not deliver an Election Notice within the applicable Election Period or
otherwise waives its Option (an “Option Lapse”), the Selling Parties may consummate the transactions contemplated by the Definitive Agreement with the Proposed Acquiror on the Offered Terms and at the Offered Price; provided
that if the Selling Parties or the Proposed Acquiror terminate such Definitive Agreement, the Option shall again apply and the Selling Parties shall be prohibited from entering into any subsequent Definitive Agreement, or consummating any subsequent
proposed Sale Transaction (in each case, other than with Humana (or its designated Affiliate)), unless the process set forth in this Section 3.1 is again complied with. 

(d) Notwithstanding the foregoing or anything in this Agreement to the contrary, if the Selling Parties or the Proposed Acquiror waive the
terms and conditions of the Definitive Agreement, or enter into an amended Definitive Agreement with different Offered Terms and/or Offered Price, then Humana shall also have an Option with respect to the proposed Sale Transaction contemplated by
such waived or amended Definitive Agreement, on the terms set forth in this Section 3.1. 
 3.2 Notwithstanding the
foregoing or anything in this Agreement to the contrary, from and after the Effective Date, (a) the Selling Parties shall not consummate, or enter into any Definitive Agreement providing for, any Sale Transaction if the Proposed Acquiror is
United HealthGroup Incorporated or an Affiliate thereof, and (b) the holders of equity securities of Cano Intermediate shall not transfer or sell any equity securities of Cano Intermediate to United HealthGroup Incorporated or an Affiliate
thereof. Notwithstanding the foregoing or anything in this Agreement to the contrary, from and after the Effective Date, Cano Intermediate agrees to take all actions necessary (including, in the case of Cano Intermediate, by including restrictive
prohibitions in its limited liability company agreement) to ensure that, upon the exchange or conversion of equity securities of Cano Intermediate for shares of Pubco, such holder(s) of equity securities of Cano Intermediate shall (i) represent
and warrant to Cano Intermediate that such exchange and/or conversion is not being consummated for the purpose of, or the intent to, transfer or sell any equity securities of Cano Intermediate (or shares of Pubco or any other Person into which they
may be convertible) to United HealthGroup Incorporated or an Affiliate thereof in one transaction or in a series of related transactions (such representation and warranty, the “United Representation”) and (ii) covenant to Cano
Intermediate that such holder(s) of equity securities of Cano Intermediate shall not transfer or sell any equity securities of Cano Intermediate (or shares of Pubco or any other Person into which they may be convertible) to United HealthGroup
Incorporated or an Affiliate thereof in one transaction or in a series of related transactions (such covenant, the “United Covenant”). In the event any holder of equity securities of Cano Intermediate breaches the United
Representation or the United Covenant, each of Cano and Pubco acknowledge and agree that such Person shall enforce any and all rights, and shall not waive any right, which such Person has or may have relating to, arising from or in connection with
such breach of the United Representation or the United Covenant, as applicable. For the avoidance of doubt, upon the exchange or conversion of equity securities of Cano Intermediate for shares of Pubco, any sale of such shares of Pubco made by a
broker in the open market to United HealthGroup Incorporated or an Affiliate thereof shall not constitute a breach of the United Representation, the United Covenant or this Agreement. 

3.3 Notwithstanding the foregoing or anything in this Agreement to the contrary, from and after the Effective Date, each Selling Party shall
provide Humana with thirty (30) calendar days’ advanced written notice of the date upon which such Person intends to initiate a Sale Process (such date, the “Sale Process Initiation Date”) along with access to any
information, if any, that is complete and available at such time and that such Selling Party intends to share with prospective 

  
 5 

 
acquirors in the Sale Process from and after the Sale Process Initiation Date. If any Sale Process is initiated, notwithstanding the foregoing or anything in this Agreement to the contrary, such
Selling Party shall include Humana in that Sale Process in substantially the same manner as other bidders, including without limitation, by providing Humana with access to all of the material non-public due
diligence information provided by, or on behalf of, the Selling Parties to other bidders in connection with the proposed Sale Transaction. 

3.4 Notwithstanding the foregoing or anything in this Agreement to the contrary, from and after the Effective Date, after entering into a
Definitive Agreement with a Proposed Acquiror for a proposed Sale Transaction, (a) such Selling Party shall not consummate such Sale Transaction prior to the occurrence of an Option Lapse with respect to such Sale Transaction and (b) in
the event that Humana delivers an Election Notice with respect to any proposed Sale Transaction, such Selling Party shall promptly terminate the Definitive Agreement with the Proposed Acquiror. Notwithstanding the foregoing or anything in this
Agreement to the contrary, from and after the Effective Date, the Selling Parties shall not consummate, or enter into any Definitive Agreement providing for, any Sale Transaction if the Definitive Agreement does not expressly provide that
(i) the Selling Parties and the Proposed Acquiror shall not be permitted to consummate such Sale Transaction prior to the occurrence of an Option Lapse with respect to such Sale Transaction and (ii) the Selling Parties have the right to
terminate such Definitive Agreement in order to comply with their obligations under this Agreement, without Humana or any of its Affiliates, or any Persons who would be Affiliates of Humana after giving effect to the consummation of the Sale
Transaction pursuant to Humana’s election of its Option, being required to pay, or being liable for, any termination fees, damages, expenses or other fees or liabilities in connection with any such termination (it being understood and agreed
that, to the extent that the Selling Parties are, or agree to be, liable for any such fees or liabilities in a Definitive Agreement, such fees and liabilities shall be fully and finally satisfied by the Selling Parties (other than any Selling
Parties who would be Affiliates of Humana after giving effect to the consummation of the Sale Transaction pursuant to Humana’s election of its Option) prior to the consummation of a Sale Transaction with Humana, to the extent that Humana elects
to exercise its Option hereunder with respect to such Sale Transaction). 
 3.5 Notwithstanding the foregoing or anything in this Agreement
to the contrary, upon any Option Lapse with respect to a particular Sale Transaction, Humana shall be deemed to have waived any other right of first refusal or similar right that it may have under any contract or agreement that it maintains with
Cano, Cano Intermediate, Pubco or any of their respective Affiliates solely with respect to such Sale Transaction; provided, that the foregoing waiver does not constitute any waiver of rights with respect to any Sale Transaction that is
consummated on terms and conditions other than the Offered Price and Offered Terms for such Sale Transaction; provided, further, for the avoidance of doubt, that Humana shall not be deemed to have waived any other right of first
refusal or similar right that it may have under any contract or agreement that it maintains with Cano, Cano Intermediate, Pubco or any of their respective Affiliates in connection with a transaction that does not constitute a Sale Transaction. 

  
 6 

 4. REPRESENTATIONS. 

Each of the parties hereto hereby represents and warrants to the other party that: (a) it is a corporation or other entity duly organized
and validly existing under the laws of the applicable state of its incorporation or organization, and has all requisite power and authority to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby;
(b) this Agreement has been duly authorized, executed and delivered by such party and it constitutes the legal, valid and binding obligations of such party, and it is enforceable against such party in accordance with its terms, except to the
extent such enforceability may be limited by bankruptcy, reorganization, insolvency or similar laws of general applicability governing the enforcement of the rights of creditors; and (c) neither the execution, delivery and performance of this
Agreement nor the consummation by such party of the transactions contemplated hereby will violate or conflict with or constitute a default under any contractual obligation of such party, or any judgment, order or decree applicable to, or binding
upon, such party. 
 5. COVENANTS. 
 5.1
Further Assurances. At any time and from time to time, either party will, without further consideration and at the other party’s expense, take such further action and execute and deliver such further instruments and documents as may be
reasonably requested by the other party in order to carry out the provisions and purposes of this Agreement. 
 5.2 Confidentiality.
Each of the parties hereto agrees that it will, except as required by applicable law or regulation (in which case any disclosure shall be limited to only such information as is required under such law or regulation) keep confidential and will not
disclose, divulge, or use for any purpose the existence or terms of this Agreement, including the terms of any proposed transactions contemplated herein; provided that Cano, Cano Intermediate, Pubco or any of their respective Affiliates may
disclose the existence of this Agreement and its obligations hereunder (without disclosing Humana’s identity) to potential acquirors on a “need to know” basis, if required in order to receive offers or proposals relating to any Sale
Transaction from any potential acquirers; provided, however, that the disclosing party shall be responsible for any breach of this Section 5.2 by any such potential acquirors as if they were party hereto. 

6. MISCELLANEOUS. 
 6.1 Notices.
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by an internationally recognized
overnight courier service, by e-mail or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties hereto at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section 6.1): 
 (a) if to Humana: 

Humana Inc. 
 500 W. Main Street

 Louisville, Kentucky 40202 

Attention: Joseph Ruschell 

  
 7 

 (b) if to Cano, Cano Intermediate or Pubco: 

c/o Cano Health, LLC 
 9725 NW
117 Avenue, Second Floor 
 Miami, FL 33178 

Attn: Dr. Marlow Hernandez, CEO 

Email: mhernandez@canohealth.com 

with a copy to (which notice shall not constitute notice): 

Goodwin Procter LLP 
 100
Northern Avenue 
 Boston, MA 02210 

Attn: Chris Wilson 
 Email:
cwilson@goodwinlaw.com 
 6.2 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced by any law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not
affected in any manner materially adverse to either party hereto. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement
so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible. 

6.3 Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement of the parties hereto with
respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written and oral, between the parties with respect to the subject matter hereof and thereof. 

6.4 Assignment. None of the parties hereto may assign this Agreement or any of his, her or its rights and obligations under this
Agreement without the prior written consent of the other party hereto; provided, that the assignee in each such instance expressly assumes all obligations imposed on the assigning party by this Agreement in writing; provided,
further, that a change of control of Humana Inc. (through stock sale, merger, or otherwise and regardless of whether Humana Inc. is the surviving entity in such a transaction) shall not constitute an assignment that requires the consent of
Cano pursuant to this Section 6.4. 
 6.5 Amendment. This Agreement may not be amended or modified except by
an instrument in writing executed by Humana, Cano, and Pubco. 
 6.6 Waiver. As amongst the parties hereto, any party hereto may
(a) extend the time for the performance of any of the obligations or other acts of the other party, (b) waive any inaccuracies in the representations and warranties of the other party contained herein or in any document delivered by the
other party pursuant hereto or (c) to the extent permitted by applicable law, waive compliance with any of the agreements of the other party or conditions to such party’s 

  
 8 

 
obligations contained herein. Any such extension or waiver shall be valid only if set forth in an instrument in writing signed by the party to be bound thereby. Any waiver of any term or
condition shall not be construed as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any party hereto to assert any of its rights
hereunder shall not constitute a waiver of any of such rights. 
 6.7 No Third Party Beneficiaries. This Agreement shall be binding
upon and inure solely to the benefit of the parties hereto and their respective successors and permitted assigns and nothing herein is intended to or shall confer upon any other person any legal or equitable right, benefit or remedy of any nature
whatsoever, including any rights of employment for any specified period, under or by reason of this Agreement. 
 6.8 Other Remedies;
Specific Performance. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party,
and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any provision of this Agreement is not performed in accordance with its
specific terms or is otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any federal or
state court located in the State of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity. 

6.9 Interpretive Rules. The words “hereof,” “herein” and “hereunder” and words of similar import when used
in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement, and all Section references are to this Agreement unless otherwise specified. The words “include,” “includes” and
“including” will be deemed to be followed by the phrase “without limitation.” The word “days” means calendar days unless otherwise specified herein. The headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement. No provision of this Agreement shall be construed to require any party or their respective officers, directors, subsidiaries or Affiliates to take any action which
would violate or conflict with any applicable law. The word “if” means “if and only if.” The word “or” shall not be exclusive. The meanings given to terms defined herein will be equally applicable to both the singular
and plural forms of such terms. Whenever the context may require, any pronoun includes the corresponding masculine, feminine and neuter forms. 

6.10 Governing Law; Consent to Jurisdiction. This Agreement shall be governed by, and construed in accordance with, the laws of the
State of Delaware, without giving effect to principles of conflicts of law. EXCEPT AS OTHERWISE SET FORTH HEREIN, EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE COURTS OF THE STARE OF DELAWARE AND TO
THE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE STARE OF DELAWARE FOR THE PURPOSE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, AND EACH OF SUCH PARTIES HEREBY IRREVOCABLY AGREES THAT ALL CLAIMS IN RESPECT TO
SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED EXCLUSIVELY IN ANY DELAWARE STATE OR FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES 

  
 9 

 
THAT A FINAL JUDGMENT IN ANY ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. EACH OF THE
PARTIES HERETO IRREVOCABLY CONSENTS TO THE SERVICE OF THE SUMMONS AND COMPLAINT AND ANY OTHER PROCESS IN ANY OTHER ACTION OR PROCEEDING RELATING TO THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, ON BEHALF OF ITSELF OR ITS PROPERTY, BY THE PERSONAL
DELIVERY OF COPIES OF SUCH PROCESS TO SUCH PARTY. NOTHING IN THIS SECTION 6.10 SHALL AFFECT THE RIGHT OF ANY PARTY TO SERVE LEGAL PROCESS IN ANY OTHER MANNER PERMITTED BY LAW. 

6.11 Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, and
by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. 

6.12 Non-Circumvention. Each party hereby covenants and agrees that such party will not, by
sale, lease, license, transfer, conveyance or other disposition, directly or indirectly, in one transaction or a series of related transactions (including by way of merger, consolidation, recapitalization, exchange offer, spin-off, split-off, reorganization or sale of securities), or by the taking of any other action, knowingly enter into and/or consummate any transaction, or series of related
transactions, with the intent to (a) circumvent or avoid the observance or performance of any of the terms of this Agreement or (b) indirectly accomplish that which it is not permitted to accomplish directly under this Agreement. 

[Signature Page Follows] 

  
 10 

 Exhibit 10.13 

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized. 
  

			
	HUMANA:
	
	HUMANA INC.
		
	By:	 	  

	Name:
	Title:
	
	HUMANA MEDICAL PLAN, INC.
		
	By:	 	
                     
    

	Name:
	Title:
	
	HUMANA HEALTH INSURANCE COMPANY OF FLORIDA, INC.
		
	By:	 	  

	Name:
	Title:
	
	HUMANA INSURANCE COMPANY 
		
	By:	 	  

	Name:
	Title:
	
	CANO:
	
	PRIMARY CARE (ITC) HOLDINGS, LLC
		
	By:	 	  

	Name:
	Title:

  
 11 

 IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed as
of the date first written above by their respective officers thereunto duly authorized. 
  

			
	CANO INTERMEDIATE:
	
	PRIMARY CARE (ITC) INTERMEDIATE HOLDINGS, LLC
		
	By:	 	              

	Name:
	Title:
	
	PUBCO:
	
	CANO HEALTH, INC.
		
	By:	 	              

	Name:
	Title:

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]